Edinburgh, Scotland-based ImmunoSolv is merging with Aberdeen's Grampian BioConsultants, combining the two companies' technical know-how to further explore the biology of cell death. ImmunoSolv also announced that it has raised £500,000 from Grampian BioPartners, the Scottish Enterprise Scottish Co-Investment Fund and the University of Edinburgh.
The new company will operate under the ImmunoSolv name, combining a complementary "portfolio of immunology and immuno-technology expertise." The funding will be used to grow the combined business, recruit a business development manager, and provide more R&D opportunities. The company hopes to have its first products in the clinic by 2012.
"...[T]he addition of GBC will ensure the company has the infrastructure, reach and product offerings to meet the needs of lab- based scientists, bio-manufacturers and clinicians in the fields of therapeutic cells and proteins worldwide," says ImmunoSolv CEO Ruth Murray.
- take a look at the Business7 report